Artivion, Inc. has closed its acquisition of Endospan, an Israel-based developer of endovascular solutions for complex aortic arch disease. The deal, valued at $175 million less offsets for prior loans, includes up to an additional $200 million in contingent consideration based on U.S. commercial performance of the NEXUS system over the next two years. The transaction follows the FDA’s PMA approval of the NEXUS® Aortic Arch Stent-Graft System in April 2026.
Endospan’s NEXUS is the first off-the-shelf endovascular stent-graft designed to treat aortic arch aneurysms and chronic dissections in patients at high risk for open surgery. The system is already commercially available in international markets. Artivion has served as the exclusive distributor of NEXUS in EMEA since 2019 and will now integrate the technology into its global portfolio alongside AMDS and ARCEVO LSA solutions.
The acquisition creates the only company with a complete aortic arch treatment portfolio spanning open, endovascular and hybrid approaches. It also brings Endospan’s pipeline of aortic arch technologies to Artivion, strengthening its long-term innovation in complex aortic repair. Endospan, headquartered in Herzliya, Israel, will support broader U.S. commercial launch efforts while maintaining strong international presence in Europe, Asia-Pacific and Latin America.
According to data captured in the LevinPro HC database, this marks the 38th Medical Device deal of the year. There were 86 Medical Device deals reported in 2025, and 87 in 2024.
